A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for t
Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusio
Scientists have developed a new test for a biomarker in brain tissue that could detect people who will go on to develop motor neuron disease (MND) before they show symptom
Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putti
Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous i